Akero Therapeutics (AKRO) News Today $49.23 +0.94 (+1.95%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$49.03 -0.20 (-0.41%) As of 08/22/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Algert Global LLC Buys 15,195 Shares of Akero Therapeutics, Inc. $AKRO1 hour ago | marketbeat.comRussell Investments Group Ltd. Buys 156,223 Shares of Akero Therapeutics, Inc. $AKRO2 hours ago | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Akero Therapeutics, Inc. $AKRO2 hours ago | marketbeat.comVanguard Group Inc. Has $171.26 Million Stock Position in Akero Therapeutics, Inc. $AKRO3 hours ago | marketbeat.comWellington Management Group LLP Sells 1,440,721 Shares of Akero Therapeutics, Inc. $AKROAugust 22 at 5:05 AM | marketbeat.comAberdeen Group plc Increases Position in Akero Therapeutics, Inc. $AKROAugust 21 at 4:17 AM | marketbeat.comFox Run Management L.L.C. Takes $642,000 Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 19, 2025 | marketbeat.comLord Abbett & CO. LLC Acquires Shares of 527,004 Akero Therapeutics, Inc. (NASDAQ:AKRO)August 18, 2025 | marketbeat.comE Fund Management Co. Ltd. Purchases New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 17, 2025 | marketbeat.comDeutsche Bank AG Sells 39,681 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)August 17, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Upgraded to Hold at Wall Street ZenAugust 17, 2025 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Upgraded by Wall Street Zen to Hold RatingAugust 17, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 12,500 Shares of StockAugust 15, 2025 | marketbeat.comAndrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAugust 15, 2025 | marketbeat.comLifesci Capital Analysts Raise Earnings Estimates for AKROAugust 15, 2025 | marketbeat.comAkero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trialAugust 14, 2025 | msn.comAkero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASHAugust 14, 2025 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 12,500 SharesAugust 14, 2025 | insidertrades.comInformed Momentum Co LLC Buys New Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 14, 2025 | marketbeat.comLifesci Capital Brokers Increase Earnings Estimates for AKROAugust 14, 2025 | americanbankingnews.comAigen Investment Management LP Purchases Shares of 20,253 Akero Therapeutics, Inc. (NASDAQ:AKRO)August 13, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Down 5.8% - Here's WhyAugust 12, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Beats Estimates By $0.09 EPSAugust 10, 2025 | marketbeat.com201,168 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Vivo Capital LLCAugust 9, 2025 | marketbeat.comJefferies Financial Group Inc. Invests $324,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 9, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $616,250.00 in StockAugust 8, 2025 | marketbeat.comTimothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAugust 8, 2025 | insidertrades.comAkero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 8, 2025 | globenewswire.comTD Cowen Initiates Coverage of Akero Therapeutics (AKRO) with Buy RecommendationAugust 5, 2025 | msn.comAkero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD CowenAugust 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 11,436 Akero Therapeutics, Inc. (NASDAQ:AKRO)August 4, 2025 | marketbeat.comAllianz Asset Management GmbH Invests $518,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 3, 2025 | marketbeat.comTD Asset Management Inc Has $8.45 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)August 1, 2025 | marketbeat.comAkero Therapeutics (AKRO) Expected to Announce Earnings on FridayAugust 1, 2025 | marketbeat.com33,611 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Picton Mahoney Asset ManagementJuly 30, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Purchases Shares of 7,676 Akero Therapeutics, Inc. (NASDAQ:AKRO)July 30, 2025 | marketbeat.comVictory Capital Management Inc. Buys 27,881 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)July 30, 2025 | marketbeat.comTeachers Retirement System of The State of Kentucky Sells 9,256 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)July 26, 2025 | marketbeat.comAstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in SubgroupJuly 26, 2025 | msn.comReadystate Asset Management LP Invests $4.07 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)July 23, 2025 | marketbeat.comJennison Associates LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)July 23, 2025 | marketbeat.comKennondale Capital Management LLC Has $571,000 Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)July 22, 2025 | marketbeat.comBank of New York Mellon Corp Purchases 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)July 22, 2025 | marketbeat.comEdgestream Partners L.P. Buys Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO)July 21, 2025 | marketbeat.comXponance Inc. Buys Shares of 5,565 Akero Therapeutics, Inc. (NASDAQ:AKRO)July 20, 2025 | marketbeat.comAkero Therapeutics shares plunge on liver disease treatment’s mixed ...July 19, 2025 | marketwatch.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 SharesJuly 19, 2025 | marketbeat.comCorcept Seeks FDA Approval for Relacorilant in Ovarian CancerJuly 15, 2025 | msn.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of "Buy" by BrokeragesJuly 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)July 14, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼1.470.66▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼87▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Viatris News Ascendis Pharma A/S News Dr. Reddy's Laboratories News QIAGEN News Moderna News BridgeBio Pharma News Verona Pharma PLC American Depositary Share News Elanco Animal Health News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access